Opus Genetics: Funding, Investors & Team (Oct 2026)
Opus Genetics is a company working on gene therapies and small molecule therapies for various eye conditions. They are currently focusing on treating inherited retinal diseases, such as Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa, using gene therapies based on adeno-associated virus. Their main candidate, OPGx-LCA5, is in a Phase 1/2 trial and has shown promising results for LCA5 mutations. They also have initiatives for treating other conditions like BEST1-related retinal degeneration and diabetic retinopathy with a small molecule therapy ready for Phase 3 trials.
Opus Genetics has raised $86.7M across 5 funding rounds on record, the most recent an undisclosed round of $35.0M announced in Apr 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Opus Genetics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Opus Genetics Funding Rounds
Opus Genetics raised $1.7M in an undisclosed round announced in Jun 2024.
1 years later, an undisclosed round of $2.0M was announced in Jun 2025.
5 months later, an undisclosed round of $23.0M was announced in Nov 2025.
3 months later, an undisclosed round of $25.0M was announced in Feb 2026.
2 months later, an undisclosed round of $35.0M was announced in Apr 2026.
Opus Genetics Founders and Leadership Team
Contact details for the Opus Genetics team: 1 of 3 have an email address on file.
Start 14-day free trial →Opus Genetics Funding Compared to Other Biotechnology Startups
Opus Genetics' latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Opus Genetics in Biotechnology and Raleigh
Companies Similar to Opus Genetics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Opus Genetics Funding FAQs
What does Opus Genetics do?
Opus Genetics is a company working on gene therapies and small molecule therapies for various eye conditions. They are currently focusing on treating inherited retinal diseases, such as Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa, using gene therapies based on adeno-associated virus. Their main candidate, OPGx-LCA5, is in a Phase 1/2 trial and has shown promising results for LCA5 mutations. They also have initiatives for treating other conditions like BEST1-related retinal degeneration and diabetic retinopathy with a small molecule therapy ready for Phase 3 trials.
How much funding has Opus Genetics raised?
Opus Genetics has raised $86.7M across 5 rounds on record. The most recent is an undisclosed round of $35.0M announced in Apr 2026.
When did Opus Genetics last raise funding?
Opus Genetics' most recent funding round on record is an undisclosed round of $35.0M, announced in Apr 2026.
Who founded Opus Genetics?
FundedIQ lists Alan Meyer (Founder), Joe Schachle (Founder), Rusty Kelley (Founder) at Opus Genetics.
Where is Opus Genetics headquartered?
Opus Genetics is based in Raleigh, North Carolina, United States.
How many employees does Opus Genetics have?
Opus Genetics is in the 11-50 employee band.
How does Opus Genetics' funding compare to other Biotechnology startups?
Opus Genetics' latest round of $35.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Opus Genetics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Opus Genetics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.